受体酸化条形码在大麻素受体脱敏化中的热力学作用
1Department of Chemistry and Biochemistry, California State University Northridge, CA, 91330, USA.
Biochemical and biophysical research communications
|December 18, 2024
概括
结构模型揭示了CB2受体酸化是如何稳定β-arrestin-2结合的,这表明了免疫细胞信号失敏的机制,并指导了对偏见的CB2受体 (CB2) 途径的药物发现.
科学领域:
- 生物化学 生物化学
- 分子药理学分子药理学
- 结构生物学 结构生物学
背景情况:
- 内分泌系统涉及CB1和CB2的G蛋白合受体 (GPCR).
- 在免疫细胞上发现的CB2受体,通过Gi蛋白和β-arrestin-2传递信号.
- 通过逮捕因的受体酸化终止了G蛋白信号传递,并启动了逮捕因介导的途径.
研究的目的:
- 阐明CB2受体信号的结构和热力学基础.
- 了解β-arrestin-2如何与酸化和非酸化CB2受体相互作用.
- 为治疗应用提供对偏差信号的见解.
主要方法:
- 生成与酸化和非酸化CB2受体复合的β-arrestin-2的结构模型.
- 在脂质双层环境中的分子动力学 (MD) 模拟.
- 对受体-阿雷斯复合物的结构和热力学分析.
主要成果:
- 与酸化CB2受体相结合的β-arrestin-2复合体与非酸化形式相比,表现出增强的稳定性.
- 酸化显著稳定了β-arrestin-2/CB2复合体,表明其在脱敏化中的作用.
- 化复合物比G蛋白复合物更稳定,这表明阿斯特林在终止G蛋白信号传递中的作用.
结论:
- 受体酸化在CB2受体信号传递中起着关键的热力学作用.
- 这些发现支持一种酸化信号受体脱敏和阿雷斯结合的模型.
- CB2信号的结构和热力学场景可以指导药物发现的偏向激动剂的发展.
更多相关视频
相关概念视频
01:12GPCR Desensitization
5.8K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
5.8K
01:22Amplifying Signals via Enzymatic Cascade
8.3K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.3K
01:20Desensitization and Tachyphylaxis
1.5K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.5K
01:29The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
01:09GPCRs Regulate Adenylyl Cylase Activity
5.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.3K
01:22Opioid Receptors: Overview
510
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
510